NeuroPace (NPCE) Stock Price, News & Analysis

Company Overview

NeuroPace, Inc. (NASDAQ: NPCE) is a medical technology company headquartered in Mountain View, California, that focuses on the development and commercialization of implantable neuromodulation systems for the treatment of neurological disorders. Founded in 1997, the company’s primary mission is to harness real-time brain data to deliver targeted therapy for patients with drug-resistant epilepsy. NeuroPace has grown from a research-driven startup to a commercial-stage company with a specialized focus on closed-loop neuromodulation.

The company’s flagship product, the RNS® System, is an implantable device that continuously monitors brain activity and delivers electrical stimulation when seizure activity is detected. This responsive neurostimulation technology represents the first and only closed-loop system approved by the U.S. Food and Drug Administration for adults with focal onset seizures who have not achieved seizure control through two or more antiepileptic medications. Clinical studies have demonstrated that the RNS System can significantly reduce seizure frequency and improve quality of life for eligible patients, making it a compelling alternative to open-loop neuromodulation or more invasive surgical interventions.

NeuroPace markets its RNS System directly in the United States, partnering with leading epilepsy centers and specialized neurologists to support patient selection, device implantation, and ongoing follow-up. The company also holds CE Mark approval, enabling limited distribution in select European markets, and is exploring additional partnerships and regulatory pathways to expand its international footprint. Alongside post-market studies, NeuroPace continues research into additional neurological indications that may benefit from closed-loop stimulation, reinforcing its commitment to innovation in neuromodulation.

Under the leadership of President and CEO R. Marc Dunoyer, NeuroPace’s management team and board of directors bring decades of combined experience in neuroscience, medical device development and healthcare commercialization. With an established commercial infrastructure, ongoing clinical trials and a focus on broadening its therapeutic pipeline, NeuroPace aims to advance personalized neurostimulation therapies and extend the benefits of its technology to a wider patient population worldwide.

Key Stats

• Today's Range: $9.50 to $10.27
• 50-Day Range: $9.52 to $18.13
• 52-Week Range: $5.45 to $18.98
• Volume: 232,549 shs
• Average Volume: 185,074 shs
• Market Capitalization: $312.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Moderate Buy

NeuroPace Stock Analysis - MarketRank™

NeuroPace scored higher than 70% of companies evaluated by MarketBeat, and ranked 317th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

NeuroPace has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroPace is -11.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroPace is -11.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroPace has a P/B Ratio of 35.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.45% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroPace has recently increased by 119.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroPace does not currently pay a dividend.

Dividend Growth

NeuroPace does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.45% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroPace has recently increased by 119.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.37

News Sentiment

NeuroPace has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NeuroPace this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,664,956.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NPCE Stock Analysis - Frequently Asked Questions

How have NPCE shares performed this year?

NeuroPace's stock was trading at $11.19 at the start of the year. Since then, NPCE shares have decreased by 14.9% and is now trading at $9.52.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. The firm earned $22.52 million during the quarter, compared to the consensus estimate of $21.85 million. NeuroPace had a negative trailing twelve-month return on equity of 190.84% and a negative net margin of 29.42%.
Read the conference call transcript.

When did NeuroPace IPO?

NeuroPace (NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroPace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NPCE
• CIK: 1528287
• Web: www.neuropace.com
• Phone: 650-237-2700
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroPace: $15.50
• High Price Target: $18.00
• Low Price Target: $8.00
• Potential Upside/Downside: +62.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.14 million
• Net Margins: -29.42%
• Pretax Margin: -29.42%
• Return on Equity: -190.84%
• Return on Assets: -25.08%

Debt

• Debt-to-Equity Ratio: 2.46
• Current Ratio: 6.63
• Quick Ratio: 5.70

Sales & Book Value

• Annual Sales: $79.91 million
• Price / Sales: 3.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 35.26

Miscellaneous

• Outstanding Shares: 32,800,000
• Free Float: 26,075,000
• Market Cap: $312.26 million
• Optionable: Optionable
• Beta: 1.93